Among the ten pharmacological inhibitors of cyclindependent kinases (CDKs) currently in clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against non-small-cell lung and nasopharyngeal cancers. An extensive medicinal chemistry study, designed to generate more potent analogues of roscovitine, led to the identification of an optimal substitution at the N6 position (compound CR8). An extensive selectivity study (108 kinases) highlights the exquisite selectivity of CR8 for CDK1/2/3/5/7/9. CR8 was 2-to 4-fold more potent than (R)-roscovitine at inhibiting these kinases. Cocrystal structures of (R)-CR8 and (R)-roscovitine with pCDK2/cyclin A showed that both inhibitors adopt essentially identical positions. The cellular effects of CR8 and (R)-roscovitine were investigated in human neuroblastoma SH-SY5Y cells. CR8 inhibited the phosphorylation of CDK1 and 9 substrates, with a 25-50 times higher potency compared to (R)-roscovitine. CR8 was consistently more potent than (R)-roscovitine at inducing apoptotic cell death parameters: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reduction (40-fold), lactate dehydrogenase release (35-fold), caspases activation (68-fold) and poly-(ADP-ribose)polymerase cleavage (50-fold). This improved cell death-inducing activity of CR8 over (R)-roscovitine was observed in 25 different cell lines. Altogether these results show that second-generation analogues of (R)-roscovitine can be designed with improved antitumor potential.
Introduction
A total of 518 kinases constitute the human kinome: 90 tyrosine kinases, 388 serine/threonine kinases and 40 sequences which lack a functional catalytic site (Kostich et al., 2002; Manning et al., 2002; Niedner et al., 2006) . Among the Ser/Thr kinases, the 20 cyclin-dependent kinases (CDKs) form a well-conserved family of kinases that has been extensively studied (Malumbres and Barbacid, 2005) . Thirteen of these have been demonstrated to be activated by the binding of a regulatory partner, generally (but not always) a cyclin. In conjunction with cyclins and through complex regulatory pathways, CDKs regulate various key transitions of the cell division cycle. Numerous abnormalities in the regulation and activity of CDKs have been described in tumors and have encouraged active search for pharmacological inhibitors of these kinases (reviews in Knockaert et al., 2002; Shapiro, 2006; Smith and Yue, 2006; Malumbres et al., 2007) . Over 120 CDK inhibitors have been identified and characterized (Knockaert et al., 2002; Fischer and Gianella-Borradori, 2005; Misra, 2006) , 10 of which are currently undergoing clinical evaluation as anticancer drugs (Malumbres et al., 2007) .
The 2,6,9-trisubstituted purines were among the first low molecular weight inhibitors of CDKs (reviews in Meijer and Raymond, 2003; Meijer et al., 2006) . One of these, (R)-roscovitine (CYC202, Seliciclib) reviews in Guzi, 2004 ) has now reached clinical phase 2 trials against non-small-cell lung cancer and nasopharyngeal cancer. Its strong selectivity against a small subset of kinases (Bain et al., 2003 (Bain et al., , 2007 Becker et al., 2004; Bach et al., 2005; Fabian et al., 2005) , relative lack of toxicity and limited secondary effects (McClue et al., 2002; Benson et al., 2007) , its oral bioavailability and encouraging responses observed during phase 1 trials (de la Motte and GianellaBorradori, 2004; Benson et al., 2007) have contributed to its progression through clinical investigations. However, its short half-life and rapid metabolism to inactive derivatives (Nutley et al., 2005; Raynaud et al., 2005; Vita et al., 2005; McClue and Stuart, 2007) , its rather weak potency on CDKs (submicromolar range) and cell lines (micromolar range; reviewed in Meijer et al., 2006) and, consequently, the large quantities required to treat patients may constitute a limiting factor in its clinical use. Therefore second-generation analogues of roscovitine, associating the qualities of roscovitine with improved potency and thus lower amounts to be delivered, are quite desirable.
In this context, we have pursued an intensive search for improved analogues of roscovitine, taking into account their ability to interact with CDKs (guided by CDK/roscovitine crystal structures), to maintain high kinase inhibition and selectivity, and to induce cell death at much lower concentrations (Oumata et al., 2008) . Although numerous modifications on positions 2 and 9 of the purine ring have been described, variations of the substituent on position 6 have been somewhat less extensively investigated (Havlicek et al., 1997; Meijer et al., 1997; Gray et al., 1998; Chang et al., 1999; Legraverend et al., 2000; Haesslein and Jullian, 2002; Vandromme et al., 2006) . This prompted us to explore biaryl substituents at N6. Surprisingly, the first N6-biaryl-substituted molecules turned out to display much stronger cell death-inducing activity compared to roscovitine, despite rather similar CDK-inhibitory action. This led us to an optimized compound, CR8, the biological characterization of which is reported here. Despite modest improvement in its CDK-inhibitory action, CR8 induces apoptotic cell death with about 50-fold enhanced potency compared to (R)-roscovitine. This effect, observed in 25 different cell lines, suggests that second-generation analogues of (R)-roscovitine can be generated with improved antitumor potential.
Results
Using a classical medicinal chemistry approach designed to identify new 2,6,9-trisubstituted CDK-inhibitory purines with improved antitumor properties, we have synthesized a series of 6-aminomethylene-biaryl analogues of (R)-roscovitine (Oumata et al., 2008) . Among this wide family of compounds we selected, for further biological evaluation, CR8, a roscovitine analogue bearing a 2-pyridyl substituent on position 4 of its phenyl ring (Figure 1 ).
CR8, an inhibitor selective for CDK1, 2, 5, 7, 9 We first tested the two isomers of CR8 and (R)-roscovitine on a small panel of 10 purified kinases (Table 1) . Results show that both CR8 isomers were potent inhibitors of CDK1, 2, 5 and 9. Both isomers were 2-to 4-fold more potent than (R)-roscovitine at inhibiting these kinases. Casein kinase 1 (CK1) d/e was inhibited with a 7-to 10-fold higher potency than (R)-roscovitine. As (R)-CR8 was more inhibitory on glycogen synthase kinase (GSK-3a/b) than its (S) isomer, (S)-CR8 was selected for further biological investigations. To complement our selectivity studies, (S)-CR8 was run on three large-scale selectivity panels (Supplementary material, Tables S1-S3): ProQinase (32 kinases), Cerep (44 kinases) and Professor P Cohen's kinase selectivity panel (76 kinases). Altogether these panels, covering 108 different kinases, confirmed the exquisite selectivity of (S)-CR8 for CDKs, with the exception of CDK4 and 6.
Cocrystallization of (R)-roscovitine and (R)-CR8 with CDK2/cyclin A To investigate the mechanisms of interaction of (R)-CR8 with its CDK targets and the molecular basis for its slightly improved inhibitory efficacy on CDKs, we cocrystallized (R)-CR8 with fully active pCDK2/cyclin A (Figures 2b, d, f; Supplementary material, Table S4, Figure S1 ). As a comparison (R)-roscovitine was also cocrystallized with pCDK2/cyclin A (Figures 2a, c, d , f). As anticipated and reported in many CDK2-inhibitor structural studies, CDK2 adopts a classical kinase bilobal fold at the interface of which the inhibitor is bound. Strong fo-fc electron density was found for both inhibitors at the adenosinetriphosphate (ATP)-binding site of CDK2. The cocrystal structure of inactive, monomeric CDK2 and (R)-roscovitine has been previously described . The comparison of (R)-roscovitine in the context of the inactive monomeric CDK2 and of the active CDK2 (phosphorylated and in complex with cyclin) reveals very little difference. The purine ring of (R)-roscovitine in the two structures occupies a very similar position along the CDK2 hinge region, making two hydrogen bonds with Leu83 main chain. Small differences in the side-chain orientation of some residues, in particular Phe80, make the inhibitor very slightly rotate toward the solvent entrance in monomeric CDK2. However, the activation of CDK2 does not significantly affect the (R)-roscovitine-binding mode. Figure S1 ). The purine ring of (R)-roscovitine and of (R)-CR8 is sandwiched between the side chain of Ile10 and of Leu134. As well as the purine rings having an identical position in the CDK2 active site, the ATP-binding site itself varies very little in the two structures. It is only in the region where the inhibitors differ that they adopt slightly different orientations. Interestingly, although partially solvent exposed and protruding out of the CDK2 ATP-binding site, the (R)-CR8 phenylpyridine substituent is supported by strong electron density. Compared to the (R)-roscovitine phenyl group, the phenyl ring of (R)-CR8 is positioned further away from the Phe82 side chain (Figures 2d-f) . The pyridine ring of (R)-CR8 points toward the solvent and the Glu8 side chain, potentially due to steric hindrance, moves slightly away to accommodate the bulky substituent of (R)-CR8 (Figures 2e and f). The pyridine ring packs in a pocket formed by Ile10, Phe82 and the alkyl portion of Glu8, possibly explaining the reason why the pyridine ring of (R)-CR8 is very well ordered in the structure.
Interestingly, the residues Glu8 and Lys89 in CDK2 are not conserved in CDK4, 7 and 9 and are substituted by smaller residues, respectively Ala and Thr for CDK4, Asp and Val for CDK7 and Ala and Gly for CDK9. This could be further analysed and potentially exploited with compounds derived from (R)-CR8 to gain selectivity within the CDK subfamily.
The dihedral angle between the phenyl and the pyridine rings in (R)-CR8 is B101 (B121 for one molecule and B81 for the second molecule present in the asymmetric unit). It is noteworthy that the inhibitory activity of compounds related to (R)-CR8 (biphenyl, 4-pyridinephenyl and 3-pyridinephenyl) is markedly reduced compared to the 2-pyridinephenyl compounds, (R)-CR8 (Table 2 ). This might be related to the propensity of the different compounds to adopt different relative orientation of the phenyl and the pyridine ring. The inhibitory activity of these compounds could be at least partially related to the phenylpyridine interplane twist angle of the most stable conformation. This would have to be investigated further to determine the exact role of the phenylpyridine substituent conformational energy in inhibitory activity.
CR8 inhibits CDKs in a cellular context
To confirm the CDK-inhibitory effects of CR8 in a cellular context we tested the effects of both (R)-CR8 and (S)-CR8 isomers on the phosphorylation of various substrates at CDK-specific sites in human neuroblastoma SH-SY5Y cells. (R)-roscovitine was tested in parallel for comparison. Briefly, cells were exposed to increasing concentrations of each compound and, after 48 h of culture, the phosphorylation of CDK substrates was investigated by SDS-polyacrylamide gel electrophoresis (PAGE) followed by western blotting with phosphospecific antibodies . Western blotting with an anti-actin antibody was used to confirm equal loading of proteins in these various protein phosphorylation and protein level analyses (data not shown). Abbreviations: CDK, cyclin-dependent kinase; GSK, glycogen synthase kinase. Compounds were tested at various concentrations for their effects on the activity of CDK1/cyclin B, CDK2/cyclin A, CDK5/p25, GSK-3a/b, CK1d/e. IC 50 values (mM) were calculated from the dose-response curves. Inhibition of phosphorylation at cyclin-dependent kinases (CDK) 1/cyclin B-specific sites on protein phosphatase 1a by (R)-roscovitine, (R)-CR8 and (S)-CR8. SH-SY5Y cells were exposed to increasing concentrations of each purine for 48 h and proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) followed by western blotting with antibodies directed against phospho-Thr320 protein phosphatase 1a. Lower concentration scale applies to CR8 isomers, whereas upper scale applies to (R)-roscovitine. Etp, etoposide.
Phosphorylation of protein phosphatase 1a (PP1a) on Thr320 (a CDK1/cyclin B-specific site; Kwon et al., 1997; Payton et al., 2006) was inhibited in a dosedependent manner by the three compounds (Figure 3 ). Both CR8 isomers were roughly 25 times more potent than (R)-roscovitine. The total level of PP1a has been assumed to be constant, although this should be demonstrated.
(R)-roscovitine induced a solid reduction of retinoblastoma protein (Rb) phosphorylation on the Ser249/ Thr252 CDK2/4 sites ( Figure 4a ). In contrast, the S-CR8 isomer did not induce any significant reduction in Rb phosphorylation on this site (Figure 4a ). Little (R)-roscovitine or no CR8 changes in total Rb protein levels were observed (Figure 4b ). No massive dephosphorylation was detected as shown by the lack of mobility shift (Figure 4b ).
RNA polymerase II is specifically phosphorylated by CDK9/cyclin T on Ser2. CR8 isomers were particularly potent at inhibiting phosphorylation of this site on this substrate (Figure 5a ). Dose-response experiments show that CR8 isomers were about 50 times more potent than (R)-roscovitine. The level of total RNA polymerase II was slightly diminished following treatment with the three compounds (Figure 5b ). Although direct inhibition of CDK9 is the most straightforward explanation, it is also possible that, in a negative feedback loop, the expression of CDK9 is reduced by roscovitine and CR8 treatment. In this context, roscovitine was recently shown to downregulate CDK9 expression in human cytomegalovirus-infected fibroblasts (Kapasi and Spector, 2008) . Furthermore, upstream activators of CDK9 may also be inhibited. Inhibition of RNA polymerase II phosphorylation and activity may thus result from the additive effects on CDK9 at several levels.
Altogether these results show that CR8 is 25-50 times more potent at inhibiting its CDK targets than (R)-roscovitine in cells.
CR8 is a potent inducer of apoptotic cell death
We next studied the cellular effects of both (R)-and (S)-isomers of CR8 using the SH-SY5Y cell line. (R)-roscovitine was tested in parallel for comparison. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reduction assays, performed 48 h after exposure to increasing concentrations of each compound, show that all three compounds reduced cell survival in a dose-dependent manner (Figure 6a ). (R)-and (S)-CR8 were roughly Inhibition of phosphorylation at cyclin-dependent kinase (CDK) 2/4-specific sites on retinoblastoma protein by (R)-roscovitine but not by (R)-CR8 and (S)-CR8. SH-SY5Y cells were exposed to increasing concentrations of each purine for 48 h and proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) followed by western blotting with antibodies directed against phospho-Rb (a) and total Rb (b). Lower concentration scale applies to the two CR8 isomers, whereas upper scale applies to (R)-roscovitine. Etp, etoposide. To verify that these effects were not restricted to the neuroblastoma cells, we tested a battery of cell lines for their sensitivity to (R)-CR8, and its tartrate salt, CR6, and (R)-roscovitine (Table 3) . Results showed that (R)-CR8 is on the average B59-fold more potent than (R)-roscovitine at compromising cell survival. Interestingly, the least sensitive cells observed were the nontransformed human foreskin fibroblasts (Table 3) . These results were independently confirmed by Oncodesign on 19 different cell lines: the average IC 50 value for (S)-CR8 and (R)-roscovitine were 2.68 and 20.21 mM, respectively (Supplementary material, Table S5 ).
Cell death induction by all three compounds was accompanied by the activation of effector caspases as measured by the fluorescence released from the AcDEVDafc synthetic caspase substrate added to the neuroblastoma SH-SY5Y cells exposed to the drugs. Dose-dependent effects and an B68-fold better potency of both (R)-and (S)-CR8 isomers over (R)-roscovitine (IC 50 values: 0.29, 0.23 and 17.8 mM, respectively) were observed (Figure 7a ). Consequently a dose-dependent induction of poly-(ADP-ribose)polymerase (PARP) cleavage (from 116 to 85 kDa) was observed (Figure 7b ). The CR8 isomers were about 50 times more potent than (R)-roscovitine at inducing PARP cleavage.
Discussion
With the initial aim of designing a CDK inhibitor that might be transported by the dopamine transporter, we recently attempted to make a hybrid molecule between roscovitine and 1-methyl-4-phenylpyridinium ion (MPP þ ). MPP þ , a monoamine oxidase metabolite of 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP), is selectively taken up by dopaminergic neuronal cells through the dopamine transporter. MPP þ is thus a selective neurotoxin of the dopamineproducing neurons in the striatum and consequently it induces striking Parkinson-like effects in animals and man. MPTP was initially accidentally produced during the illicit synthesis of a synthetic opioid displaying effects similar to those of heroin and morphine (Langston et al., 1983) . As the phenyl ring of roscovitine is facing the outside of the ATP-binding pocket, we reasoned that the MPP þ analogue moiety could be attached at the N6 position. Surprisingly, substitution at N6 by some biaryls led to molecules displaying much Cell survival was estimated by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reduction assay and is expressed in % of survival in untreated cells. Average ± s.e. of three independent measurements per experiment. (b) A similar experiment was performed but lactate dehydrogenase (LDH) release was assayed 24 h after the addition of the compounds. Average±s.e. of three independent measurements per experiment. stronger cell death-inducing activity compared to roscovitine, despite rather similar CDK inhibition. In this paper, we report on the biological properties of one of these N6-biaryl-substituted purines, CR8, a compound closely related to the well-studied clinical drug (R)-roscovitine. The only structural difference between the two compounds is the presence, at the N6 position, of a 4-(2-pyridiyl)benzyl substituent in CR8 in place of the benzyl ring in roscovitine. This modification does not result in detectable differences in the interaction between the purine ring of both inhibitors and the amino acids lining the ATP-binding site of CDK2, as shown in the inhibitor/CDK2/cyclin A crystal structures (Figure 2 ). The phenyl (roscovitine) and 4-(2-pyridiyl)benzyl (CR8) substituents are facing the outside of the ATP-binding pocket. They are orientated in a similar planar direction, and the phenyl-4-(2-pyridine) (CR8) substituent packs itself against a relatively apolar crevice in the vicinity of the selectivity surface. However, the slight increase in inhibitory activity of CR8 is not totally clear from the analysis of the crystal structures. Despite these strong binding mode similarities, CR8 was found to be significantly more potent at inhibiting CDKs but also the few other kinase targets of (R)-roscovitine ( Table 1 ). The reason for this modest but consistent improvement of the kinase-inhibitory properties of CR8 versus (R)-roscovitine remains to be understood. In terms of kinase targets, CR8 displayed essentially the same selectivity as (R)-roscovitine (Table 1 and Supplementary Tables S1-S3 ). However, it cannot be ruled out that unidentified 'off' targets interact with CR8.
When CR8 and (R)-roscovitine were compared for their cellular effects, a striking difference was observed whatever the parameters used to monitor cell responses to the drugs. Overall CR8 was 25-50 times more potent than (R)-roscovitine at inducing apoptotic cell death and its accompanying biochemical events. This effect was investigated in detail in the human neuroblastoma SH-SY5Y cell line but was also confirmed in 25 different human cell lines. In addition, we observed a similar>50-fold increase in potency of CR8 over (R)-roscovitine at inducing cell death in nondividing B2-chronic lymphoid leukemia cells (Bettayeb et al., in preparation) . No specificity for a particular tumor type was observed. The superiority of CR8 over (R)-roscovitine could arise from different reasons. The cell permeability to CR8 could be better and the intracellular stability of CR8 could be longer. Under identical cell permeability and cellular stability, the intracellular distribution of CR8 and (R)-roscovitine could be quite different and this might contribute to the difference in cell death-inducing potency. CDKs indeed are located in the cytoplasm, the centrosomes, the Golgi apparatus and the nucleus. However, no information is available on the precise CDK target localization, the inhibition of which leads to cell death induction. Another difference between CR8 and (R)-roscovitine that might account for their difference in cell death-inducing potency is the scope of their intracellular targets. Extensive investigations on wide panels of protein kinases (Table 1; Supplementary  Tables S1-S3 ) did not reveal major differences between CR8 and (R)-roscovitine in their kinase targets. The modest difference in inhibitory potency of CR8 over (R)-roscovitine on the main targets does not account for the major difference in cell death-inducing potency. However, it is possible that modest differences on a small set of key kinases may add up, resulting in a major cellular effect. In this context the 7-to 10-fold increase in CK1-inhibitory effects of CR8 over (R)-roscovitine may synergize with the 2-to 4-fold increase in CDK inhibition. Specific inhibition of CK1 has been shown to lead to cell death (Behrend et al., 2000; review in Knippschild et al., 2005) . Nevertheless, we cannot rule out an unknown specific target (kinase or nonkinase) of CR8 that would not be affected by (R)-roscovitine. Another possibility that could explain the cellular differences between the two purines is that, in contrast to (R)-roscovitine, CR8 may not interact with a nonrelevant, 'buffering' target. If so, under identical uptake, metabolism, intracellular distribution and similar affinity to kinase targets, the effective concentration of CR8 available to trigger cell death might be increased quite substantially whereas a significant fraction of (R)-roscovitine is trapped by the irrelevant target, leaving only a small subfraction available to trigger cell death. To identify and compare the different targets of CR8 and (R)-roscovitine present in the sensitive cell lines, we are attempting to immobilize CR8 on an agarose matrix to affinity purify its protein targets, a method that has been successfully used with (R)-roscovitine . Given the structural similarity between CR8 and (R)-roscovitine, their similar kinase-inhibitory profile, it is not surprising that they induce similar molecular responses, leading ultimately to similar apoptotic cell death. We are currently comparing the key intracellular events underlying this cell death induction pathway. Inhibition of CDKs involved in cell-cycle regulation (CDK1, 2) and control of transcription (CDK7, 9) appears to contribute to the induction of cell death, as demonstrated recently using combined inhibition of specific CDKs by small interfering RNAs and inhibitors (Cai et al., 2006) . In this context, we have demonstrated enhanced inhibition of CDK1 (specific phosphorylation of protein phosphatase; Figure 3 ) and CDK9 (specific phosphorylation of RNA polymerase II; Figure 5 ) by CR8 over (R)-roscovitine. We have observed downregulation of the survival factor Mcl-1 and a transient appearance of free antiapoptotic protein Noxa (Bettayeb et al., unpublished) . This is in accordance with previously observed results obtained with (R)-roscovitine (see Hallaert et al., 2007, and references therein) . Similarly, inhibition of CDK1 in Myc-overexpressing cells leads to rapid downregulation of the survival factor survivin and induction of cell death (Goga et al., 2007) . We believe that these effects also result from the conjunction of CDK1/2 and 7/9 inhibition. Altogether these results suggest that, like (R)-roscovitine, CR8 acts by a combination of independent effects, resulting in the downregulation of survival factors, and consequently the effective induction of apoptotic cell death.
In conclusion, we have shown here that a relatively minor alteration of the roscovitine scaffold, in an area which lies outside of the ATP-binding pocket, was able to lead to an unexpectedly important improvement of the cell death-inducing activity of this purine family, despite only modest increase in the kinase inhibition properties. This increase in antiproliferative activity of the roscovitine derivatives has been observed in vitro and it remains to be demonstrated that enhanced in vivo antitumor activity will be maintained in animal models. These second-generation analogues of roscovitine should now be investigated for their toxicity and antitumor properties in appropriate animal models.
Materials and methods
Chemistry (R)-roscovitine was synthesized as previously described (Tang et al., 2005; Meijer et al., 2006) The synthesis of (R)-CR8 and (S)-CR8 will be described in detail elsewhere (Oumata et al., 2008) . Compounds were stored dry, but diluted as 10 mM stock solutions in dimethylsulfoxide (DMSO).
Crystallography
Expression, purification and cocrystallization of human CDK2/ cyclin A with CR8 or (R)-roscovitine Thr160-phosphorylated CDK2/cyclin A (pCDK2/cyclin A) was purified as described previously (Brown et al., 1999) and concentrated to 13 mg/ml in 40 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, pH 7.0), 200 mM NaCl, 0.01% monothioglycerol and stored at 193 K until further use. The protein solution was incubated 20 min on ice with (R)-CR8 (2 mM) or (R)-roscovitine (2 mM). Before setting up the hanging drop crystallization trials, the protein solution was filtered through a 0.2 mm filter unit to remove protein aggregates and precipitated inhibitor. The reservoir solution contained 0.6-0.8 M KCl, 0.9 DMSO 1.2 M (NH 4 ) 2 SO 4 and 100 mM HEPES (pH 7.0). Orthorhombic crystals grew within a few weeks at 4 1C. Crystals were briefly cryoprotected in 8 M sodium formate before being cryocooled in liquid nitrogen.
X-ray crystallography data collection and processing, structure solution and refinement. Data were collected from a single crystal on ESRF ID14-EH-2 and ID14-EH-1 beamline (Grenoble, France) at 100 K for pCDK2/cyclin A/(R)-roscovitine and for pCDK2/cyclin A/(R)-CR8, respectively. Data processing and integration were carried out using MOSFLM and SCALA (CCP4, 1994) . The structures in complex with (R)-roscovitine and with the (R)-CR8 inhibitor were solved by molecular replacement with MOLREP using a well-refined structure of pCDK2/cyclin A (J Endicott and A Echalier, unpublished results) as the search model. The asymmetric unit in the two inhibitor structures contained two CDK2/cyclin A heterodimers. The presence of the inhibitor was confirmed by the presence of strong electron density at the ATP site after rigid body refinement of the structures. The structure refinement to 1.8 Å (R)-roscovitine and 2.7 Å for (R)-CR8, the inhibitor model building and the library generation for (R)-roscovitine and (R)-CR8 were performed using the CCP4 software suite (CCP4, 1994) . Alternate cycles of rebuilding in Coot (Emsley and Cowtan, 2004) and refinement in Refmac (Murshudov et al., 1997) were carried out to obtain the final models. Data processing and refinement statistics of pCDK2/ cyclin A/(R)-roscovitine and pCDK2/cyclin A/(R)-CR8 structures are presented in Table S1 (Supplementary information).
Protein kinase assays Buffers. Buffer A: 10 mM MgCl 2 , 1 mM EGTA, 1 mM dithiothreitol (DTT), 25 mM Tris-HCl (pH 7.5), 50 mg heparin per ml.
Buffer C: 60 mM b-glycerophosphate, 15 mM p-nitrophenyl phosphate, 25 mM Mops (pH 7.2), 5 mM EGTA, 15 mM MgCl 2 , 1mM DTT, 1 mM sodium vanadate and 1 mM phenylphosphate.
Kinase preparations and assays. Kinase activities were assayed in buffer A or C, at 30 1C, at a final ATP concentration of 15 mM. Blank values were subtracted and activities expressed in % of the maximal activity, that is, in the absence of inhibitors. Controls were performed with appropriate dilutions of DMSO.
CDK1/cyclin B (M-phase starfish oocytes, native), CDK2/ cyclin A, CDK2/cyclin E, CDK5/p25 and CDK7/cyclin H (human, recombinant) were prepared as previously described (Bettayeb et al., submitted) . Their kinase activity was assayed in buffer C, with 1 mg histone H1 per ml, in the presence of 15 mM [g-33 P] ATP (3000 Ci/mmol; 10 mCi/ml) in a final volume of 30 ml. After 30 min incubation at 30 1C, 25 ml aliquots of supernatant were spotted onto 2.5 Â 3 cm pieces of Whatman P81 phosphocellulose paper, and, 20 s later, the filters were washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters were counted in the presence of 1 ml ACS (Amersham, Les Ulis, France) scintillation fluid.
CDK9/cyclin T (human, recombinant, expressed in insect cells) was assayed as described for CDK1/cyclin B, but using a pRB fragment (amino acid, 773-928) (3.5 mg per assay) as a substrate.
GSK-3a/b (porcine brain, native) was assayed, as described for CDK1 but in buffer A and using a GSK-3-specific substrate (GS-1: YRRAAVPPSPSLSRHSSPHQSpEDEEE) (pS stands for phosphorylated serine) . GS-1 was synthesized by MilleGen (Labege, France).
CK1 (porcine brain, native) was assayed as described for CDK1 but using the CK1-specific peptide substrate RRKHAAIGpSAYSITA (Reinhardt et al., 2007) , obtained from MilleGen.
Erk2 (rat, recombinant) was assayed as described for CDK1 but using the specific substrate Ets1 (amino acids, 1-138) in buffer A.
DYRK1A (rat, recombinant, expressed in Escherichia coli as a glutathione S-transferase fusion protein) was purified by affinity chromatography on glutathione-agarose and assayed as described for CDK1/cyclin B using myelin basic protein (1 mg/ml) as a substrate.
Cell biology Antibodies and chemicals. AcDEVDafc was purchased from MP biomedicals (Vannes, France). Cell Titer 96 containing the MTS reagent and CytoTox 96 kits were purchased from Promega (Madison, WI, USA). The protease inhibitor cocktail was from Roche (Penzberg, Germany). Unless otherwise stated, the non-listed reagents were from Sigma (St Quentin Fallavier, France).
Monoclonal antibodies against actin were from Calbiochem (Madison, WI, USA). Monoclonal antibodies against Rb were purchased from BD Biosciences (San Diego, CA, USA). Polyclonal antibody against phospho-Ser249/Thr252-Rb was provided by Biosource (Camarillo, CA, USA). Polyclonal antibody against phospho-Thr320-PP1a was from Cell Signalling (Danvers, MA, USA). Polyclonal antibodies against RNA polymerase II and phospho-Ser2-RNA polymerase II were supplied by Covance Research Products (Berkeley, CA, USA). Polyclonal antibodies against PARP were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Homogenization buffer. b-Glycerophosphate (60 mM), 15 mM p-nitrophenyl phosphate, 25 mM MOPS (pH 7.2), 15 mM EGTA, 15 mM MgCl 2 , 1mM dithiothreitol, 1 mM sodium vanadate, 1 mM NaF, 1 mM phenylphosphate, 0.1 % Nonidet P-40 and protease inhibitor cocktail.
Cell lines and culture conditions. SH-SY5Y human neuroblastoma (kindly provided by Dr Jacint Boix, Lleida), Huh7 human hepatocarcinoma and LS 174T human colorectal adenocarcinoma cell lines were grown in DMEM medium from Invitrogen (Cergy Pontoise, France). The HCT116 human colorectal carcinoma cell line was grown in McCoy's 5a medium from ATCC (Manassas, VA, USA). The F1 rat biliary epithelial cell line (kindly provided by Dr Christiane Guillouzo, Rennes) was grown on Williams' Medium E from Invitrogen supplemented with 2 mM L-glutamine from Lonza (Verviers, Belgium). The HEK 293 human embryonic kidney cell line (kindly provided by Dr Jan Mester, Paris) was grown in minimum essential medium from Invitrogen. Human foreskin primary fibroblasts (kindly provided by Dr Gilles Ponzio, Nice) were grown in DMEM supplemented with 2 mM L-glutamine and 20 mM HEPES. All the media were supplemented with antibiotics (penicillin-streptomycin) from Lonza and 10% volume of fetal calf serum from Invitrogen. Cells were cultured at 37 1C with 5% CO 2 . Drug treatments were performed on exponentially growing cultures at the indicated time and concentrations. Control experiments were carried also using appropriate dilutions of DMSO.
Cell death and cell viability assessments. Cell viability was determined by measuring the reduction of MTS. Cell death was determined by measuring the level of LDH activity released upon cell lysis. Both procedures have been previously described in detail (Ribas and Boix, 2004) .
Caspase assay. Caspase activity was measured by determining the fluorescence released from the AcDEVDafc synthetic substrate after its direct addition to the culture medium, detergent lysis and incubation at 37 1C. This method is devised to be applied to 96 multiwell plates (Ribas et al., 2006a, b) .
Electrophoresis and western blotting. Cells were resuspended, lysed for 30 min at 4 1C in homogenization buffer and sonicated. After centrifugation (14000 r.p.m. for 15 min at 4 1C), the protein concentration was determined in the supernatants by the Bradford protein assay (Bio-Rad, Marnes-la-Coquette, France). Following heat denaturation for 5 min, proteins were separated by 10 or 7% NuPAGE pre-cast Bis-Tris or Tris-acetate polyacrylamide mini gel electrophoresis system (Invitrogen) with MOPS SDS (all but RNA polymerase II and phospho-Ser2-RNA polymerase II western blots), or Tris-acetate SDS (RNA polymerase II and phospho-Ser2-RNA polymerase II) running buffer depending on protein size. Proteins were transferred to 0.45 mm nitrocellulose filters (Schleicher and Schuell). These were blocked with 5% low-fat milk in Tris-buffered saline-Tween-20, incubated for 1 h with antibodies (anti-actin: 1:2000) or overnight at 4 1C (Rb (1:500), phospho-Rb (1:500), phospho-Thr320-PP1a (1:1000), RNA polymerase II (1:500), phospho-Ser2-RNA polymerase II (1:500), PARP (1:500), p53 (1:1000), p27 KIP1 (1:1000) and analysed by enhanced chemiluminescence (ECL, Amersham).
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